Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216868 | 0.79 | ALDH1A1 (0.35) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL8955156 | 0.79 | MEN1 (0.42) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL27388 | 0.77 | APOBEC3G (0.46) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| Benzene SCHEMBL7199484 | 0.74 | PDCD1 (0.46) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL11862358 | 0.70 | APOBEC3G (0.41) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL167807 | 0.69 | HSPA5 (0.44) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL30182764 | 0.69 | HSPA5 (0.44) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL9712092 | 0.68 | TDP1 (0.39) | APOBEC3G | |
| SCHEMBL16961000 | 0.68 | GABRA1 (0.39) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 | |
| SCHEMBL620083 | 0.67 | TAAR1 (0.42) | APOBEC3GGABRA1GABRG2GABRB3PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349856-B1 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1349856-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6482951-B2 | ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GUERTIN KEVIN RICHARD (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048106-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GCKR, GCK, PGK2 | APOBEC3G 4415/4885GABRA1 1577/4885GABRG2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.